Categories: News

Sharps Compliance To Present at Stifel 2021 Virtual Cross Sector Insight Conference

HOUSTON, June 02, 2021 (GLOBE NEWSWIRE) — Sharps Compliance Corp. (Nasdaq: SMED) announced today that David P. Tusa, President and Chief Executive Officer, will make a presentation at the Stifel 2021 Virtual Cross Sector Insight Conference at 9:20 a.m. ET on Thursday, June 10, 2021 and will also be available to conduct one-on-one meetings throughout the day.

The Sharps Compliance presentation will be available at the following link:

https://wsw.com/webcast/stifel47/smed/2085602

About Sharps Compliance Corp.

Headquartered in Houston, Texas, Sharps Compliance (NASDAQ: SMED) is a leading business-to-business services provider to the healthcare, long-term care and retail pharmacy markets. Sharps Compliance offers comprehensive solutions for the management of regulated medical waste, hazardous waste and unused medications. For more information, visit: www.sharpsinc.com.

Company Contact: Diana Diaz
  Sharps Compliance Corp.
  Email: ddiaz@sharpsinc.com
  Office: (713) 660-3547
   
Investor Contact: John Nesbett/Jennifer Belodeau
  Institutional Marketing Services
  Email: jnesbett@institutionalms.com
  Office: (203) 972-9200

                                                                         

                
                                                         
                                                                         
                                                                         

 

Staff

Recent Posts

BioHarvest Launches VINIA SuperFood Functional Tea Line

Incremental Product Launch Addresses $3.3 Billion North American Functional Tea Market Opportunity with First SuperFood…

34 minutes ago

Neurotech Innovator UNEEG Medical Receives FDA Breakthrough Device Designation Within Monitoring and Diagnostic of Epilepsy

The designation is a result of UNEEG's strong focus on developing novel disease management support…

34 minutes ago

Lexaria’s GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC /…

34 minutes ago

S4 Medical Receives FDA 510(k) Approval for its Redesigned Esophageal Deviation Device and Begins Commercialization

CHAGRIN FALLS, OH / ACCESSWIRE / November 25, 2024 / S4 Medical Corp, an Ohio…

34 minutes ago

Acreage Provides Update on Corporate Transactions

NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Acreage Holdings, Inc. ("Acreage" or…

34 minutes ago